Supriya Lifescience Ltd (SUPRIYA) shares are rising Today, April 22, 2026, due to a Big Live breakout of 6%, reaching an intraday high of ₹653. The rally is primarily fueled by the Latest Big news that the USFDA inspection at its manufacturing facility concluded with a “VAI” (Voluntary Action Indicated) rating and only one minor observation, effectively clearing the path for Big US exports. Additionally, investors are reacting to the Latest anticipation of a Big ₹4–₹6 final dividend and strong Live Q4 earnings estimates projecting a profit of up to ₹110 crore.
Supriya Lifescience USFDA VAI Rating Triggers 6% Surge – ₹6 Dividend Signal & ₹850 Price Target Explained
Quick Highlights: The Latest Big Moves
- Intraday Peak: ₹653.00 (Up 6.0% Today).
- USFDA Rating: Received “VAI” status Today, signaling a successful plant audit.
- Big Q4 Estimates: Revenue expected at ₹350–380 Cr; PAT estimated at ₹96–110 Cr.
- Latest Dividend News: Board to meet in May to consider a Big ₹4–6 per share payout.
- Live Performance: The stock has staged a Big recovery of 12% in the last 30 days.
Key Market Data (Live: April 22, 2026)
| Metric | Latest Value | Big Performance Trend |
| Current Market Price (NSE) | ₹652.95 | +₹31.95 (+5.25%) Today |
| 52-Week High / Low | ₹832.40 / ₹545.50 | Live Bullish Reversal |
| Market Capitalization | ₹5,223 Crore | Big Small-cap Pharma |
| Operating Profit Margin | 34.69% | Latest Efficiency High |
| P/E Ratio (TTM) | 27.43x | Attractive Big Entry |
Why It Happened: The Big Regulatory & Earnings Boost
The Latest vertical move in Supriya Lifescience is driven by three Big fundamental triggers dominating the Live tape Today:
- USFDA Clearance: The Big news Today is the completion of the USFDA inspection at the company’s manufacturing facility. Receiving a “VAI” rating is a Latest signal of high compliance standards. This Big clearance allows the company to accelerate its Latest product launches in the regulated US market, which accounts for a Big portion of global API demand.
- Anticipation of Record Q4 Results: The Latest pre-result buzz suggests a Big quarterly performance. Analysts expect a Live EBITDA margin of 38–41%, supported by a Latest shift toward high-margin specialized APIs. Analysts expect a strong seasonal demand in the European and North American markets to drive the revenue jump.
- Dividend Confidence: Management is expected to recommend a Big final dividend of ₹4–6 per share. This higher-than-usual payout reflects the company’s strong cash flows, solid profitability, and a clean, debt-free balance sheet.
Market Context & Latest Industry Trends
The Live sentiment in the pharma API sector is turning Big as global supply chains stabilize. Today, Supriya is outperforming its Latest peers like Cohance Lifesciences. Technically, the stock cleared its Big resistance at ₹630 Today, opening up a Live path toward its Latest target of ₹850 (as projected by brokerages like Deven Choksey). The Big recovery in rural and export demand is providing a Latest floor for the stock.
Also read about Stocks With Highest FII Holding in India
What It Means for Investors
The Latest 8% jump is a Big confirmation that the “worst is over” for this API major. With the Live USFDA hurdle cleared, the Big focus now shifts to the Latest Q4 results in May. For long-term investors, the Big news is the company’s Live ability to maintain 30%+ margins. However, the 26% US reciprocal tariffs remain a key monitorable for the entire sector.
Frequently Asked Questions (FAQ)
1. Why is Supriya Lifescience share rising Today?
The stock is rising today, driven by a successful USFDA inspection (VAI rating), strong Q4 profit expectations, and an anticipated big dividend.
2. What is the Latest Big news about the USFDA inspection?
Today, reports confirmed that the USFDA concluded its audit with a Big “VAI” rating, meaning only minor issues were found, which is a Latest win for its export business.
3. What is the Latest dividend update for Supriya Lifescience?
Analysts expect a final dividend of ₹4 to ₹6 per share, likely to be considered at the upcoming board meeting in May 2026.
4. What is the Big target price for Supriya Lifescience?
Major brokerages have a Latest target of ₹850–₹940, suggesting a Big upside of over 30% from current Live levels.
Conclusion
Today, Supriya Lifescience has shown Why it is a Big contender in the global API space. The Latest regulatory win and Live earnings momentum prove that its Big focus on compliance and high-value therapies is paying off. As the Latest Q4 results approach, Supriya remains a Big “Buy” for investors seeking Live growth in the debt-free pharmaceutical segment.
Disclaimer: The views expressed are for informational purposes only and do not constitute financial advice. Investing in stocks and IPOs involves significant risk.forgeup.in is not liable for any financial losses. Always consult a certified investment advisor before making any decisions.